- Company
- Amgen
- Role
- Chairman & CEO
- Est. Net Worth
- $100 Million
- Stage
- Established
- Industry
- Healthcare
Robert Bradway
Chairman & CEO at Amgen
About
Robert Bradway has served as CEO of Amgen since 2012 and chairman since 2013, leading one of the world's largest independent biotechnology companies. A former investment banker, he joined Amgen in 2006 and rose through its finance and operating ranks.
Current Company
Amgen — Chairman & CEO
Running One of Biotech’s Largest Independents
Robert Bradway became CEO of Amgen in 2012 and Chairman in 2013, leading one of the world’s largest independent biotechnology companies through a period of significant portfolio transformation. A former investment banker who joined Amgen in 2006, Robert Bradway brought a financial discipline and strategic rigor to a company that was navigating patent cliffs on some of its legacy blockbusters while building a new generation of innovative medicines.
Under Robert Bradway’s leadership, Amgen has expanded into cardiovascular disease, oncology, and obesity — including its high-profile obesity drug program — while maintaining its leadership in inflammation, hematology, and bone health. Robert Bradway has also positioned Amgen as a leader in biosimilar medicines, creating a portfolio that brings lower-cost versions of complex biologics to patients. Robert Bradway’s strategic approach has been to balance near-term financial performance with long-term pipeline investment, keeping Amgen competitive in a rapidly evolving pharmaceutical landscape.